^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sacituzumab tirumotecan (MK-2870)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    8d
    A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (ChiCTR2400089007)
    P2, N=130, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New P2 trial • Combination therapy
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR • BRCA mutation • MSH6 expression
    |
    FoundationOne® CDx
    |
    5-fluorouracil • sacituzumab tirumotecan (MK-2870)
    17d
    A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P3 trial
    |
    Tagrisso (osimertinib) • sacituzumab tirumotecan (MK-2870)
    1m
    TroFuse-027: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    sacituzumab tirumotecan (MK-2870)
    2ms
    SKB264-II-04: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=498, Recruiting, Klus Pharma Inc. | N=278 --> 498
    Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • sacituzumab tirumotecan (MK-2870)
    3ms
    KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • sacituzumab tirumotecan (MK-2870) • levoleucovorin calcium
    4ms
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • sacituzumab tirumotecan (MK-2870) • Tivdak (tisotumab vedotin-tftv)
    4ms
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • sacituzumab tirumotecan (MK-2870)
    4ms
    Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50% (IASLC-WCLC 2024)
    AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Enrollment began in December 2023 and is currently ongoing.
    PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • TROP2 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    4ms
    A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% (ChiCTR2400083440)
    P3, N=92, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    4ms
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=98, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • sacituzumab tirumotecan (MK-2870)
    5ms
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=98, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • sacituzumab tirumotecan (MK-2870)
    5ms
    SKB264-Ⅲ-10: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • sacituzumab tirumotecan (MK-2870)
    5ms
    A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
    Enrollment open • Phase classification • Combination therapy
    |
    5-fluorouracil • sacituzumab tirumotecan (MK-2870) • levoleucovorin calcium
    5ms
    SKB264-Ⅲ-11: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=524, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • sacituzumab tirumotecan (MK-2870)
    5ms
    U1111-1301-2790: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov)
    P3, N=851, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • sacituzumab tirumotecan (MK-2870)
    5ms
    Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial • Metastases
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • sacituzumab tirumotecan (MK-2870) • levoleucovorin calcium
    5ms
    SKB264-II-04: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=278, Recruiting, Klus Pharma Inc. | Trial completion date: Apr 2026 --> Aug 2026
    Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • sacituzumab tirumotecan (MK-2870)
    5ms
    KL264-01: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (clinicaltrials.gov)
    P1/2, N=1300, Recruiting, Klus Pharma Inc. | N=430 --> 1300 | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    sacituzumab tirumotecan (MK-2870)
    5ms
    U1111-1289-8264: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (clinicaltrials.gov)
    P3, N=1530, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Surgery
    |
    Keytruda (pembrolizumab) • capecitabine • sacituzumab tirumotecan (MK-2870)
    5ms
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Metastases
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • sacituzumab tirumotecan (MK-2870) • Tivdak (tisotumab vedotin-tftv)
    5ms
    Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov)
    P3, N=520, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    carboplatin • pemetrexed • dexamethasone • sacituzumab tirumotecan (MK-2870)
    5ms
    A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=406, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    6ms
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • sacituzumab tirumotecan (MK-2870)
    6ms
    A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    5-fluorouracil • sacituzumab tirumotecan (MK-2870) • levoleucovorin calcium
    6ms
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov)
    P3, N=851, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • sacituzumab tirumotecan (MK-2870)
    6ms
    A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • sacituzumab tirumotecan (MK-2870)
    7ms
    Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (clinicaltrials.gov)
    P3, N=1530, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Surgery
    |
    Keytruda (pembrolizumab) • capecitabine • sacituzumab tirumotecan (MK-2870)
    7ms
    Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (ASCO 2024)
    Background: Sacituzumab Tirumotecan (SKB264/MK-2870)is a TROP2 ADC developed with novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. SKB264 in combination with KL-A167 demonstrated promising efficacy results in treatment naive advanced NSCLC with manageable safety profile. SKB264 Q2W was recommended for further investigation. A Phase 3 study of SKB264 Q2W plus pembrolizumab vs pembrolizumab in 1L metastatic NSCLC with PD-L1 TPS ≥ 50% (NCT06170788) is ongoing.
    Combination therapy • P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870) • Camtobell (belotecan) • tagitanlimab (HBM9167)
    7ms
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov)
    P3, N=780, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • sacituzumab tirumotecan (MK-2870)
    7ms
    A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Metastases
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • sacituzumab tirumotecan (MK-2870)
    8ms
    A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov)
    P3, N=1200, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • sacituzumab tirumotecan (MK-2870)
    8ms
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • sacituzumab tirumotecan (MK-2870)
    8ms
    A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov)
    P3, N=1200, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • sacituzumab tirumotecan (MK-2870)
    8ms
    MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov)
    P3, N=520, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Metastases
    |
    carboplatin • pemetrexed • dexamethasone • sacituzumab tirumotecan (MK-2870)
    9ms
    Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50% (AACR 2024)
    AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Enrollment began in December 2023 and is currently ongoing.
    Clinical • PD(L)-1 Biomarker • IO biomarker • Tumor proportion score • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • TROP2 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    9ms
    A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=524, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P3 trial
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • sacituzumab tirumotecan (MK-2870)
    10ms
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Feb 2025 --> Nov 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • dexamethasone • sacituzumab tirumotecan (MK-2870) • MK-4830
    11ms
    MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (clinicaltrials.gov)
    P3, N=614, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Tumor proportion score • Metastases
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    11ms
    MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (clinicaltrials.gov)
    P3, N=710, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • doxorubicin hydrochloride • sacituzumab tirumotecan (MK-2870)
    11ms
    MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (clinicaltrials.gov)
    P3, N=614, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
    11ms
    SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=110, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
    |
    cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
    11ms
    MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (clinicaltrials.gov)
    P3, N=710, Not yet recruiting, Merck Sharp & Dohme LLC | Phase classification: P2/3 --> P3
    Phase classification
    |
    paclitaxel • doxorubicin hydrochloride • sacituzumab tirumotecan (MK-2870)